|

MedlyPeds Feasibility Study

RECRUITINGN/ASponsored by The Hospital for Sick Children
Actively Recruiting
PhaseN/A
SponsorThe Hospital for Sick Children
Started2026-07
Est. completion2028-12
Eligibility
Age8 Years – 18 Years
Healthy vol.Accepted

Summary

SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.

Eligibility

Age: 8 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Consent provided.
2. Aged 8-18 years of age.
3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.)
4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:

   1. Heart failure of any etiology
   2. Congenital heart disease
   3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc)
   4. Pulmonary hypertension
   5. Post-cardiac surgery including heart transplant and ventricular assist devices

Exclusion Criteria:

1. Unable to read or write in English.
2. Participating in another clinical trial that may confound the results.\* \*Participant may be re-screened for eligibility at a later date.

Conditions6

Acquired Heart DiseaseCongenital Heart Disease (CHD)Heart DiseasePediatric Heart FailurePost-cardiac SurgeryPulmonary Hypertension

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.